LONDON, April 20, 2016 /PRNewswire/ --
Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage of Adherium
Highlights of the analysis on Adherium by Edison's healthcare analysts Dennis Hulme and Beth Senko are:
Adherium has developed the market-leading Smartinhaler platform that monitors usage of inhaled asthma and COPD medications and provides reminders and feedback that improve patient adherence. With an existing commercial relationship with AstraZeneca and strong relationships with other pharma companies and key opinion leaders through sales for clinical trials, Adherium is positioned for strong revenue growth. We value Adherium at A$188m, or A$1.31 per share.
Adherium is a digital health company developing technologies that address suboptimal medication use and remote patient management in chronic diseases. Clinical evidence shows that its Smartinhaler substantially increases adherence and reduces severe exacerbations in asthma.
Click here to view the full report.
All reports published by Edison are available to download free of charge from its website:
About Edison: We are an international equity advisory firm. We enable our client companies to achieve their capital market objectives. The team is made up of more than 80 analysts and investment professionals with many decades of experience. Our extensive company knowledge and industry expertise spans 10 business sectors and more than 700 listed companies globally. We give our corporate clients and investors privileged insight into global investment trends. Our distribution capability is key to ensuring that a global investor audience can access our investment knowledge. Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:
280 High Holborn
245 Park Avenue, 39th Floor
New York, NY 10167
Level 25 Aurora Place
88 Philip Street
Sydney NSW 2000
SOURCE Edison Investment Research